腎臓バイオマーカー：各種技術と世界の市場

世界の腎臓バイオマーカーの市場規模は、2022年の12億米ドルから、2027年には17億米ドルに成長し、2022年から2027年にかけてのCAGRは7.6％と予測されています。

濾過腎臓バイオマーカーの部門は、2022年の4億9,290万米ドルから、2027年には7億2,070万米ドルに成長し、2022年から2027年にかけてのCAGRは7.9％と予測されています。また、上方制御腎臓バイオマーカーの部門は、2022年の4億990万米ドルから、2027年には5億8,650万米ドルに成長し、CAGRは7.4%と予測されています。

当レポートでは、世界の腎臓バイオマーカーの市場を調査し、市場概要、市場成長への各種影響因子の分析、法規制環境、市場規模の推移・予測、各種区分・地域/主要国別の詳細分析、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 サマリー・ハイライト

第3章 市場概要

• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• バイオマーカーの規制プロセス

第4章 COVID-19の影響

第5章 世界の腎臓バイオマーカー市場：タイプ別

• 概要
• 濾過腎臓バイオマーカー（尿細管再吸収障害）
  • アルブミン
  • シスタチンC
  • ベータ-2ミクログロブリン
• 上方制御バイオマーカー
  • KIM-1腎障害分子
  • 好中球ゼラチナーゼ関連リポカリン
  • クラステリン
  • インターロイキン-18
  • ネトリン-1
• プレフォーム
  • アルカリホスファターゼ
  • γ-グルタミルトランスペプチダーゼ
  • グルタチオンS-トランスフェラーゼ
  • N-アセチル-BDグルコサミニダーゼ
  • 肝臓型脂肪酸結合タンパク質
  • メタロプロテアーゼ2およびインスリン様成長因子結合タンパク質7の組織阻害剤
• その他
  • 血中尿素窒素
  • セラム・クレアチン
  • 下方制御

第6章 世界の腎臓バイオマーカー市場：地域別

• 北米
• 欧州
• アジア太平洋
• その他の地域

第7章 世界の腎臓バイオマーカー市場：エンドユーザー別

• 病院
• 研究センター
• その他

第8章 世界の腎臓バイオマーカー市場：技術別

• 概要
• 酵素免疫測定法
• 粒子増強濁度イムノアッセイ
• 比色アッセイ
• 化学発光酵素イムノアッセイ
• その他

第9章 競合情勢

第10章 企業プロファイル

• ABBOTT LABORATORIES
• BECKMAN COULTER INC.
• BIOMERIEUX
• BIOPORTO A/S
• BIO-RAD
• ENZO BIOCHEM INC.
• GENTIAN DIAGNOSTIC AB
• HYTEST LTD.
• NEPHROSANT
• Nexelis
• PROTEOMICS INTERNATIONAL LABORATORIES LTD.
• RANDOX LABORATORIES LTD.
• ROCHE（F. HOFFMANN-LA ROCHE AG）
• SPHINGOTEC
• THERMO FISHER SCIENTIFIC

第11章 特許レビュー

第12章 臨床試験分析

List of Tables

• Summary Table : Global Market for Renal Biomarkers, by Segment, Through 2027
• Table 1 : Applications for Biomarkers, with Examples
• Table 2 : Changes in Aging Kidneys
• Table 3 : Qualified Biomarkers of EMA SAWP/CHMP, as of March 30, 2020
• Table 4 : Stages in the FDA Biomarker Qualification Program
• Table 5 : Qualified Biomarkers for FDA CDER BQP, as of Feb. 19, 2020
• Table 6 : Cases of COVID-19 and Related Deaths, by Country, as of October 2022
• Table 7 : Effects of COVID-19 on Kidney Disease Patients
• Table 8 : Properties of KIM-1
• Table 9 : Global Market for Renal Biomarkers, by Region, Through 2027
• Table 10 : AKI in Developed and Developing Countries
• Table 11 : North American Market for Renal Biomarkers, by Country, Through 2027
• Table 12 : North American Market for Renal Biomarkers, by Type, Through 2027
• Table 13 : U.S. Market for Renal Biomarkers, by Type, Through 2027
• Table 14 : Canadian Market for Renal Biomarkers, by Type, Through 2027
• Table 15 : European Kidney Health Alliance Recommendations
• Table 16 : European Market for Renal Biomarkers, by Region, Through 2027
• Table 17 : European Market for Renal Biomarkers, by Type, Through 2027
• Table 18 : German Market for Renal Biomarkers, by Type, Through 2027
• Table 19 : Italian Market for Renal Biomarkers, by Type, Through 2027
• Table 20 : French Market for Renal Biomarkers, by Type, Through 2027
• Table 21 : Spanish Market for Renal Biomarkers, by Type, Through 2027
• Table 22 : U.K. Market for Renal Biomarkers, by Type, Through 2027
• Table 23 : Rest of Europe Market for Renal Biomarkers, by Type, Through 2027
• Table 24 : Asia-Pacific Market for Renal Biomarkers, by Country, Through 2027
• Table 25 : Asia-Pacific Market for Renal Biomarkers, by Type, Through 2027
• Table 26 : Australian Market for Renal Biomarkers, by Type, Through 2027
• Table 27 : Japanese Market for Renal Biomarkers, by Type, Through 2027
• Table 28 : Chinese Market for Renal Biomarkers, by Type, Through 2027
• Table 29 : Rest of Asia Market for Renal Biomarkers, by Type, Through 2027
• Table 30 : RoW Market for Renal Biomarkers, by Type, Through 2027
• Table 31 : Global Market for Renal Biomarkers, by End User, Through 2027
• Table 32 : Global Market for Renal Biomarkers, by Technique, Through 2027
• Table 33 : Methods for Detection of Renal Biomarkers
• Table 34 : Company Developments, 2019-2022
• Table 35 : Abbott Laboratories: Renal Biomarker Portfolio
• Table 36 : Abbott Laboratories: Revenue and R&D Expenses, 2019 to 2021
• Table 37 : Abbott Laboratories: Revenue, by Segment
• Table 38 : BioMerieux: Revenue and R&D Expenditure, 2019-2021
• Table 39 : BioMerieux: Revenue of Immunoassay Segment, 2019-2021
• Table 40 : BioMerieux: Recent Developments, 2019-2022
• Table 41 : Bioporto: Revenue and R&D Expense, 2019-2021
• Table 42 : Bioporto: NGAL Revenue, 2019-2021
• Table 43 : Bioporto: Recent Developments, 2019-2022
• Table 44 : Bio-Rad: Kidney Toxicity Assay Portfolio
• Table 45 : Bio-Rad: Revenue and R&D Expense, 2019-2021
• Table 46 : Enzo Biochem: Revenue and R&D Expenses, 2019-2021
• Table 47 : Enzo Biochem: Revenue, by Segment, 2019-2021
• Table 48 : Enzo Biochem: Revenue, by Region, 2019 to 2021
• Table 49 : Gentian Diagnostic: Revenue, by Region, 2019-2021
• Table 50 : Gentian Diagnostic: Recent Developments, 2019-2022
• Table 51 : Nexelis: Recent Developments, 2019-2022
• Table 52 : Nexelis: Renal Biomarker Portfolio
• Table 53 : Proteomics International: Revenue, 2019-2022
• Table 54 : Proteomics: Recent Developments, 2019-2022
• Table 55 : Roche: Revenue and R&D Expenses, 2019-2021
• Table 56 : Roche: Revenue, by Segment, 2019-2021
• Table 57 : Roche: Revenue, by Diagnostic Segment, 2019-2021
• Table 58 : Roche: Revenue, by Region, 2019 to 2022
• Table 59 : Sphingotec: Recent Developments, 2019-2022
• Table 60 : Thermo Fisher Scientific: Revenue and R&D Expenses, 2019-2021
• Table 61 : Thermo Fisher Scientific: Revenue, by Segment, 2019-2021
• Table 62 : Thermo Fisher Scientific: Recent Developments, 2019-2022
• Table 63 : Precision Medicine Patent Criteria in U.S. and Europe
• Table 64 : List of Renal Biomarker Patents

List of Figures

• Summary Figure : Global Market for Renal Biomarkers, by Type, 2019-2027
• Figure 1 : Applications for Biomarkers
• Figure 2 : Timeline for Renal Biomarkers
• Figure 3 : Initial Timeline of EMA Biomarker Qualification
• Figure 4 : Flowchart of EMA Biomarker Qualification Process
• Figure 5 : Steps in EMA Biomarker Qualification
• Figure 6 : Steps in Biomarker Quantification
• Figure 7 : Pathways for Excretion of IGFBP7 and TIMP-2
• Figure 8 : Percentage of CKD Patients, by Age, in U.S.
• Figure 9 : Number of Patients Receiving Kidney Dialysis in Canada
• Figure 10 : EU Patients Undergoing Kidney Dialysis and Transplants
• Figure 11 : Shares of Leading Companies in the Renal Biomarker Market
• Figure 12 : Clinical Trials of Renal Biomarkers, by Therapeutic Area, 2019 to October 2022
• Figure 13 : Clinical Trials of Renal Biomarkers, by Sponsor
• Figure 14 : Clinical Trials of Renal Biomarkers, by Location

Highlights:

The global market for renal biomarkers is estimated to increase from $1.2 billion in 2022 to reach $1.7 billion by 2027, at a compound annual growth rate (CAGR) of 7.6% from 2022 through 2027.

The global market for filtered renal biomarker products is estimated to increase from $492.9 million in 2022 to reach $720.7 million by 2027, at a CAGR of 7.9% from 2022 through 2027.

The global market for upregulated renal biomarker products is estimated to increase from $409.9 million in 2022 to reach $586.5 million by 2027, at a CAGR of 7.4% from 2022 through 2027.

Report Scope:

This report incorporates an in-depth analysis of the renal biomarker market, including market estimations and trends through 2021. Major players, competitive intelligence, innovative technologies, market dynamics and regional opportunities are discussed in detail. The report examines recent developments and product portfolios of major players. The patent analysis focuses on technological trends in recent years in regions such as the U.S., Europe, and Japan. The report presents a market analysis and estimates the CAGR for renal biomarkers.

The scope of the report extends only to renal biomarker consumables and not devices used to study renal biomarkers. All types of renal biomarkers have been considered in research, clinical trials and for diagnostic purposes.

This report segments the global market by these geographic regions: North America, Europe, Asia-Pacific, and the Rest of the World (RoW) region. For market estimates, data is provided for 2021 as the base year, 2022 and forecast through year-end 2027.

Report Includes:

• 41 data tables and 24 additional tables
• A detailed overview and up-to-date analysis of the global markets for renal biomarkers
• Analyses of the global market trends, with market revenue data for 2019-2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
• Estimation of the actual market size and revenue forecast for renal biomarkers market, and corresponding market share analysis by assay type, application, end user, and region
• Updated information on market drivers and opportunities for renal biomarkers, key shifts, regulations and industry specific challenges, and other demographic factors that will shape the market demand over the coming years (2022-2027)
• Identification of the companies best positioned to meet the demand owing to their proprietary technologies, product launches, mergers and acquisitions, and other market strategic advantages
• Review of recent industry structure for biomarkers, R&D activities, and analysis of the competitive landscape based on recent developments and segmental revenues
• Patent activity and review of patent grants for biomarkers and related technologies
• Descriptive company profiles of the market leading players, including BioMerieux, Gentian Diagnostic, Proteomics International, Thermo Fisher Scientific, SphingoTec, and BioPorto

Table of Contents

Chapter 1 Introduction

• 1.1 Study Goals and Objectives
• 1.2 Reasons for Doing this Study
• 1.3 What's New in this Report
• 1.4 Scope of Report
• 1.5 Information Sources
• 1.6 Methodology
• 1.7 Geographic Breakdown
• 1.8 Analyst's Credentials
• 1.9 BCC Custom Research
• 1.10 Related BCC Research Reports

Chapter 2 Summary and Highlights

Chapter 3 Market Overview

• 3.1 Introduction
  • 3.1.1 Kidneys
  • 3.1.2 Renal Biomarkers
  • 3.1.3 Definition
• 3.2 Market Dynamics
  • 3.2.1 Drivers
  • 3.2.2 Restraints
  • 3.2.3 Opportunities
• 3.3 Regulatory Process for Biomarkers
  • 3.3.1 European Medicines Agency
  • 3.3.2 Biomarkers Qualified by the FDA

Chapter 4 Impact of COVID-19 Pandemic

• 4.1 Impact of COVID-19 on Renal Biomarker Market
  • 4.1.1 Increased Incidence of AKI
  • 4.1.2 Other Diseases
• 4.2 Chronic Dialysis Patients
  • 4.2.1 Kidney Transplant Recipients

Chapter 5 Global Renal Biomarker Market by Type

• 5.1 Overview
• 5.2 Filtered Renal Biomarkers (Impaired Tubular Reabsorption)
  • 5.2.1 Albumin
  • 5.2.2 Cystatin C
  • 5.2.3 Beta-2 Microglobulin
• 5.3 Upregulated Biomarkers
  • 5.3.1 KIM-1 Kidney Injury Molecule
  • 5.3.2 Neutrophil Gelatinase Associated Lipocalin
  • 5.3.3 Clusterin
  • 5.3.4 Interleukin-18
  • 5.3.5 Netrin-1
• 5.4 Preformed
  • 5.4.1 Alkaline Phosphatase
  • 5.4.2 Gamma-Glutamyl Transpeptidase
  • 5.4.3 Glutathione S-Transferase
  • 5.4.4 N-acetyl-B-D Glucosaminidase
  • 5.4.5 Liver-Type Fatty Acid-Binding Protein
  • 5.4.6 Tissue Inhibitor of Metalloprotease-2 and Insulin-Like Growth Factor-binding Protein 7
• 5.5 Other Biomarkers
  • 5.5.1 Blood Urea Nitrogen
  • 5.5.2 Serum Creatinine
  • 5.5.3 Downregulated

Chapter 6 Global Market for Renal Biomarkers by Region

• 6.1 North America
  • 6.1.1 United States
  • 6.1.2 Canada
• 6.2 Europe
  • 6.2.1 Germany
  • 6.2.2 Italy
  • 6.2.3 France
  • 6.2.4 Spain
  • 6.2.5 United Kingdom
  • 6.2.6 Rest of Europe
• 6.3 Asia-Pacific
  • 6.3.1 Australia
  • 6.3.2 Japan
  • 6.3.3 China
  • 6.3.4 Rest of Asia
• 6.4 Rest of the World

Chapter 7 Renal Biomarker Market by End User

• 7.1 Hospitals
• 7.2 Research Centers
• 7.3 Other End Users

Chapter 8 Renal Biomarker Market by Technique

• 8.1 Overview
• 8.2 Enzyme Linked Immunosorbent Assay
• 8.3 Particle-Enhanced Turbidimetric Immunoassays
• 8.4 Colorimetric Assays
• 8.5 Chemiluminescent Enzyme Immunoassays
• 8.6 Other Detection Methods

Chapter 9 Competitive Landscape

Chapter 10 Company Profiles

• ABBOTT LABORATORIES
• BECKMAN COULTER INC.
• BIOMERIEUX
• BIOPORTO A/S
• BIO-RAD
• ENZO BIOCHEM INC.
• GENTIAN DIAGNOSTIC AB
• HYTEST LTD.
• NEPHROSANT
• Nexelis
• PROTEOMICS INTERNATIONAL LABORATORIES LTD.
• RANDOX LABORATORIES LTD.
• ROCHE (F. HOFFMANN-LA ROCHE AG)
• SPHINGOTEC
• THERMO FISHER SCIENTIFIC

Chapter 11 Patent Review

Chapter 12 Clinical Trial Analysis